Penumbra (PEN)
(Delayed Data from NYSE)
$210.12 USD
+12.55 (6.35%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $209.94 -0.18 (-0.09%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$210.12 USD
+12.55 (6.35%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $209.94 -0.18 (-0.09%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum C VGM
Zacks News
Here's Why You Should Invest in IDEXX (IDXX) Right Now
by Zacks Equity Research
Investors continue to be optimistic about IDEXX (IDXX) on the strength of the Companion Animal Group business.
Bruker's (BRKR) Latest Workflows to Aid Applied Markets
by Zacks Equity Research
Bruker (BRKR) introduces Novel EVOQ DART-TQ+ for chromatography-free mass spectrometry for applied markets.
Here's Why You Should Invest in Edward Lifesciences (EW) Now
by Zacks Equity Research
Investors continue to be optimistic about Edward Lifesciences (EW) on the strength of the Surgical Structural Heart business and the Critical Care segment.
Should iShares Morningstar Small-Cap ETF (ISCB) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ISCB
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) on the strength of the base business performance and its strategies to accelerate growth.
LabCorp (LH) Expands Precision Oncology With Biopsy Test
by Zacks Equity Research
The addition of Labcorp Plasma Focus marks a pivotal step in the expansion of LabCorp's (LH) suite of precision oncology tests.
Illumina (ILMN) to Present Real-World CGP Data at ASCO Meet '23
by Zacks Equity Research
At the ASCO meeting, Illumina (ILMN) is set to showcase data that highlights better outcomes for cancer patients who receive comprehensive genomic testing.
Here's Why You Should Retain Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Medtronic (MDT) on the robust performances of the Neurosurgery and Cardiovascular portfolios.
Here's Why You Should Retain Integra (IART) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Integra Lifesciences (IART) based on the prospect of its CSS segment and ample liquidity to support M&A strategies.
Here's Why You Should Retain Tandem Diabetes (TNDM) Now
by Zacks Equity Research
Investors continue to be optimistic about Tandem Diabetes (TNDM) based on the strong performance of the t:slim X2 insulin pump.
Medtronic's (MDT) EV ICD Pivotal Study Shows Favorable Outcome (Revised)
by Zacks Equity Research
Medtronic (MDT) announces that the findings of the EV ICD Pivotal Study reinforce device safety and effectiveness.
Here's Why You Should Retain Globus Medical (GMED) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Globus Medical (GMED) based on the strong performances across geographies and the pending NuVasive acquisition.
Myriad Genetics (MYGN) Adds New Test to Oncology Portfolio
by Zacks Equity Research
Myriad Genetics (MYGN) expands Precise Oncology Solutions portfolio by adding a new biomarker test.
Here's Why You Should Retain Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Bruker Corporation (BRKR) based on the strong performances of CALID and BioSpin Group and its raised 2023 outlook.
Boston Scientific (BSX) Gains From Acquisitions, New Launches
by Zacks Equity Research
Boston Scientific (BSX) remains excited about 2023 performance and expects to continue to outpace its peers within the EMEA market.
Abbott (ABT) Unveils Late-Breaking Data on Leadless Pacemaker
by Zacks Equity Research
Abbott (ABT) study analyzes primary safety and efficacy endpoints in the first 300 people enrolled across 55 centers in the United States, Canada and Europe.
Medtronic's (MDT) EV ICD Pivotal Study Shows Favorable Outcome
by Zacks Equity Research
Medtronic (MDT) announces that the findings of the EV ICD Pivotal Study reinforce device safety and effectiveness.
Here's Why You Should Retain Chemed (CHE) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Chemed (CHE) on the strong performance of the VITAS Healthcare and Roto-Rooter segments.
Exact Sciences (EXAS) Gains From New Buyouts Amid High Costs
by Zacks Equity Research
Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is now offering therapy selection tests for patients with advanced cancer.
Here's Why You Should Retain Insulet (PODD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Insulet (PODD) on the robust performance of Omnipod 5.
Zacks.com featured highlights Penumbra, Lamb Weston, Transportadora de Gas del Sur and AeroVironment
by Zacks Equity Research
Penumbra, Lamb Weston, Transportadora de Gas del Sur and AeroVironment have been highlighted in this Screen of The Week article.
Thermo Fisher (TMO) Gets FDA Clearance for Its Immunoassays
by Zacks Equity Research
Thermo Fisher (TMO) announces the FDA clearance of its blood-based biomarkers used in the determination of risk assessment and clinical management of preeclampsia with severe features.
Buy These 4 Low-Beta Stocks to Sail Through Market Volatility
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Penumbra (PEN), Lamb Weston (LW), Transportadora (TGS) and AeroVironment (AVAV) are poised to gain.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
QIAGEN (QGEN) is likely to benefit from high organic growth across its non-COVID-19 product group and portfolio advancements, reflecting a positive share price movement.
Should iShares Morningstar Small-Cap Growth ETF (ISCG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ISCG